Loading
Burning Rock's personalised blood test for leftover lung cancer after surgery, which tracks up to 50 of the tumour's own mutations.
PROPHET (Patient-specific pROgnostic and Potential tHErapeutic marker Tracking) was described by Burning Rock Biotech and Chinese surgical groups in Cancer Cell in 2023: deep sequencing of 50 patient-specific variants, a stated limit of detection of 0.004 per cent, and 760 plasma samples from 181 prospectively enrolled patients with early-stage non-small cell lung cancer. It detected tumour DNA before surgery in 45 per cent of patients, outperformed fixed-panel assays for prognosis, and gave a median lead time of 299 days to radiologically confirmed recurrence. Of the variants it tracked, 98.2 per cent were not canonical driver mutations.
Burning Rock states in a press release of 25 August 2026 that its CanCatch Custom kit entered China's NMPA special review procedure for innovative medical devices; that is entry to review, not registration, and was not checked on the NMPA site.
Whole-exome sequencing of tumour and white blood cells selects up to 50 patient-specific variants, which a personalised capture panel then reads deeply in plasma with molecular barcodes.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"brPROPHET" OR ABSTRACT:"brPROPHET" OR TITLE:"PROPHET" OR ABSTRACT:"PROPHET" OR TITLE:"Burning Rock PROPHET" OR ABSTRACT:"Burning Rock PROPHET" OR TITLE:"Patient-specific pROgnostic and Potential tHErapeutic marker Tracking" OR ABSTRACT:"Patient-specific pROgnostic and Potential tHErapeutic marker Tracking") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about brPROPHET, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/